What Is LL-37 and Why Researchers Study It
LL-37 is the only human cathelicidin-derived antimicrobial peptide, a 37-residue cationic peptide beginning with two leucine residues, which gives the molecule its name. It is enzymatically cleaved from the precursor protein hCAP18 and has become a widely studied model in the field of host-defense peptide research.
Researchers investigate LL-37 because it sits at the intersection of innate immunity, membrane biology, and inflammation signaling. In preclinical research models, studies explore how this cationic, amphipathic peptide interacts with microbial membranes and how it may participate in immunomodulatory signaling cascades. Its broad presence across epithelial surfaces, neutrophils, and other cell types makes it a compelling subject for laboratories examining the innate immune response.
At Amino Labs, LL-37 (5mg) is supplied as a lyophilized powder at 99%+ HPLC purity for laboratory research applications. This educational overview summarizes what the peptide is, the mechanisms researchers investigate, and the handling considerations relevant to reproducible in-vitro work. All discussion here is framed strictly within a scientific, research-use-only context.
Recommended Products
Mechanisms and Research Directions Investigators Explore
The research literature surrounding LL-37 spans several mechanistic themes. Because the peptide is cationic and amphipathic, studies explore how it associates with negatively charged microbial membrane surfaces in model systems. Investigators use techniques such as membrane-mimetic vesicle assays and structural spectroscopy to characterize these interactions in controlled laboratory settings.
Beyond membrane-interaction studies, researchers investigate LL-37 as a signaling molecule within the innate immune system. Preclinical research suggests roles that laboratories continue to map, including:
- Immunomodulation: how the peptide may influence cytokine and chemokine expression in cultured cell models.
- Chemotaxis: studies exploring receptor interactions relevant to immune-cell recruitment in vitro.
- Wound and tissue models: research examining angiogenesis and epithelial responses in laboratory assays.
- Inflammation signaling: investigations into how LL-37 interacts with nucleic acids and pattern-recognition pathways.
Because LL-37 overlaps mechanistically with other host-defense and immune-signaling compounds, laboratories frequently study it alongside related peptides. Researchers comparing anti-inflammatory signaling often examine it in parallel with KPV (10mg), while those focused on immune modulation may reference work on Thymosin Alpha-1 (10mg). These comparative approaches help contextualize LL-37 within the broader innate-immunity research landscape and remain strictly investigational.
Research Handling, Reconstitution, and Sourcing
Reliable LL-37 research depends on careful handling. As a lyophilized peptide, LL-37 (5mg) should be stored desiccated and protected from light, with long-term storage typically at freezer temperatures. Researchers generally allow sealed vials to reach room temperature before opening to reduce condensation on the powder.
For reconstitution in laboratory protocols, investigators commonly dissolve peptides using sterile or bacteriostatic water, adding solvent gently down the vial wall rather than directly onto the pellet. Once reconstituted, the solution is best kept refrigerated and used within a defined working window. Researchers minimize freeze-thaw cycles, since repeated cycling can compromise peptide integrity and assay reproducibility; aliquoting before freezing is a common mitigation.
Purity and sourcing directly affect experimental validity. Amino Labs supplies LL-37 at 99%+ HPLC purity, lyophilized and third-party tested, from a Canadian-owned operation that ships across Canada. Laboratories studying cationic peptides alongside LL-37 may also reference handling notes for VIP (10mg), which shares similar reconstitution and cold-chain considerations for research use.